# Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

> **NCT07195227** · PHASE2 · NOT_YET_RECRUITING · sponsor: **MedSIR** · enrollment: 150 (estimated)

## Conditions studied

- Hormon Receptor Positive Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** Camizestrant
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT07195227
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-02
- **Final completion:** 2028-03
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07195227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07195227, "Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07195227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*